Lineage Cell Therapeutics' (LCTX) Buy Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Lineage Cell Therapeutics, with a price target of $2.00, indicating a potential upside of 106.19% from the stock's previous close.
• HC Wainwright also maintains a "buy" rating" but with a higher price target of $9.00, and five research analysts collectively rate the stock as a "buy" with a consensus target price of $4.20.
• Lineage Cell Therapeutics has recently seen increased investment, with 62.47% of its stock currently owned by institutional investors and hedge funds, showcasing growing confidence in the company's potential.

D. Boral Capital reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Free Report) in a report published on Tuesday,Benzinga reports. D. Boral Capital currently has a $2.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Monday, June 23rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $4.20.

Lineage Cell Therapeutics Stock Up 3.5%

NYSEAMERICAN LCTX traded up $0.03 during trading hours on Tuesday, hitting $0.98. The company's stock had a trading volume of 657,585 shares, compared to its average volume of 1,558,615. The stock has a fifty day moving average of $0.94 and a 200 day moving average of $0.66. Lineage Cell Therapeutics has a twelve month low of $0.37 and a twelve month high of $1.21. The firm has a market capitalization of $224.80 million, a P/E ratio of -12.31 and a beta of 1.66.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Advisers LP boosted its stake in shares of Lineage Cell Therapeutics by 312.2% during the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock valued at $44,000 after purchasing an additional 65,864 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Lineage Cell Therapeutics during the fourth quarter valued at approximately $152,000. Barclays PLC boosted its stake in shares of Lineage Cell Therapeutics by 10.8% during the fourth quarter. Barclays PLC now owns 234,069 shares of the company's stock valued at $118,000 after purchasing an additional 22,769 shares during the period. Comerica Bank boosted its stake in shares of Lineage Cell Therapeutics by 220.0% during the fourth quarter. Comerica Bank now owns 800,000 shares of the company's stock valued at $402,000 after purchasing an additional 550,000 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Lineage Cell Therapeutics by 1,058.3% during the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company's stock valued at $1,147,000 after purchasing an additional 2,085,972 shares during the period. Hedge funds and other institutional investors own 62.47% of the company's stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.